Zoe Goddard

Zoe Goddard

Auto-generated profile, based on publicly available information

Zoe Goddard

University of East Anglia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
ZGZoë Rachael Goddard
Zoë Rachael Goddard
MMMaría J. Marín
María J. Marín
DRDavid A. Russell
David A. Russell
MSMark Searcey
Mark Searcey
Gold nanoparticles are excellent delivery systems, but how can we get them where we want them to go?

19 November 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
ZGZoë Rachael Goddard
Zoë Rachael Goddard
ABAndrew Michael Beekman
Andrew Michael Beekman
MCMarco M. D. Cominetti
Marco M. D. Cominetti
MOMaria A. O'Connell
Maria A. O'Connell
ICIsabelle Chambrier
Isabelle Chambrier
MSMark Searcey
Mark Searcey
Gold nanoparticles, covalently functionalised with the photosensitiser C11Pc and PEG, were actively targeted towards epidermal growth factor receptor overexpressing cancers using the peptide FITC-βAAEYLRK, with selective phototoxicty observed.

9 July 2024 in Chemical Communications
Verified
Journal Article
Open access
PDF file
DHDeanne Hayward
Deanne Hayward
ZGZoë R. Goddard
Zoë R. Goddard
MCMarco M. D. Cominetti
Marco M. D. Cominetti
MSMark Searcey
Mark Searcey
ABAndrew M. Beekman
Andrew M. Beekman
A photoswitch peptide that binds to PD-1/PD-L1 only in the cis conformation, allowing for external control of the immune checkpoint interaction.

1 May 2021 in Tetrahedron Letters
Verified
Journal Article
Closed access
MCMarco M.M.D. Cominetti
Marco M.M.D. Cominetti
ZGZoë R. Goddard
Zoë R. Goddard
CHChloe E. Howman
Chloe E. Howman
MOMaria A. O'COnnell
Maria A. O'COnnell
MSMark Searcey
Mark Searcey

4 March 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
DHDeanne Hayward
Deanne Hayward
ZGZoe Goddard
Zoe Goddard
MCMarco Cominetti
Marco Cominetti
MSMark Searcey
Mark Searcey
ABAndrew Beekman
Andrew Beekman
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments. Limitations of antibody treatments remain prevalent leaving an urgent need for alternative inhibitors of PD-1/PD-L1. Utilizing the photo-switching ability of the well studied azobenzenes, we developed a photo-controlled PD-1/PD-L1 peptide inhibitor. The azobenzene peptide selectively inhibits the PD-1/PD-L1 interaction when in the cis isomer, while showing no appreciable inhibition in the trans isomer. The light-activated inhibitor demonstrated improved activity compared to the canonical peptide it was derived from in a luminescent cell-based PD-1/PD-L1 blockade assay. The light-activated peptide demonstrates the applicatbilty of photoisomerization for mimicking β-hairpin motifs in PD-1/PD-L1 inhibition.

24 April 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
MCMarco Cominetti
Marco Cominetti
ZGZoe Goddard
Zoe Goddard
BHBethany Hood
Bethany Hood
ABAndrew Beekman
Andrew Beekman
MOMaria O'COnnell
Maria O'COnnell
MSMark Searcey
Mark Searcey
The synthesis of the ethyl ester analogue of the ultapotent antitumour antibiotic seco-duocarmycin SA has been achieved in eleven linear steps from commercially available starting materials. The DSA alkylation subunit can be made in ten linear steps from the same precursor. The route involves CH activation at the equivalent of the C7 position on indole leading to a borylated intermediate 9 that is stable enough for coupling reactions but can be easily converted to the free hydroxyl analogue.